Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 18/20 | 0.73 |
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.60 |
| ▸ | SRPK2 | P78362 | 2/20 | 0.60 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897343 | 1.00 | ALK (0.73) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL16775678 | 0.88 | ALK (0.66) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL897360 | 0.87 | ALK (0.65) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL897572 | 0.86 | SRPK1 (0.72) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL897528 | 0.86 | ALK (0.92) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL20004657 | 0.85 | ALK (0.63) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL897212 | 0.85 | ALK (0.66) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL1755862 | 0.85 | ALK (0.63) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL15061912 | 0.85 | ALK (0.78) | ALKSRPK1SRPK2EML4 | |
| SCHEMBL897073 | 0.84 | ALK (1.00) | ALKSRPK1SRPK2EML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110891947-B | Process for preparing ailutinib or a pharmaceutically acceptable salt thereof | 北京费森尤斯卡比医药有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-11465999-B2 | Process for preparing Alectinib or a pharmaceutically acceptable salt thereof | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465999-B2 | Process for preparing Alectinib or a pharmaceutically acceptable salt thereof | PLEC, SF3B5, FCGR3B | ALK 78/4885SRPK1 1689/4885SRPK2 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.